Introducing the “Chemical Transformations Podcast: the art of unlocking sustainable commercial potential”
May 7, 2021
Welcome to CCD Partners’ newly launched Chemical Transformations podcast!
Businesses built on expertise in chemistry or biology often face unique challenges realising and sustaining their full commercial potential.
Throughout our newly-launched podcast series "Chemical Transformations Podcast: the art of unlocking sustainable commercial potential" we will be interviewing dealmakers and business leaders to learn about the challenges they are facing and the strategies they have employed to get ahead and stay ahead.
In our inaugural episode, CCD Partners Managing Partner Matt Dixon and Senior Advisor Glenn McGuire discuss the sale of Chem32 to PQ Corporation, recent performance trends in the specialty chemicals markets, and how investor confidence has evolved a year on from the COVID-19 pandemic outbreak.
Episode 1: Glenn McGuire
CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.
To organise a call with one of our partners please email contact@ccdpartners.com
Receive M&A news relevant to your business
At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free
Contact Us
RECENT POSTS

In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.

Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products.

Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.